Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2009

View Archived Issues

GeoVax requests pre-IND meeting with FDA for therapeutic AIDS vaccine

Chugai is granted additional approvals in China for Xeloda and Avastin

EMEA accepts for review Pharming's MAA for Rhucin for hereditary angioedema

2009 influenza A (H1N1) vaccine generates immune response in children

Alimera Sciences starts pilot study of Iluvien in patients with macular edema

Alizyme provides update on sale of Cetilistat

BioSante and Cell Genesys confirm final exchange ratio for merger

Nifurtimox/eflornithine combination therapy for sleeping sickness now available

Pluristem Therapeutics doses first patient in phase I trial for PAD

Protalix Biotherapeutics presents preclinical data on pr-anti-TNF for arthritis

Sangamo BioSciences plans to initiate second CCR5-ZFP trial in HIV/AIDS

TGen commences clinical trials for OSI-906 for adrenocortical carcinoma

Icagen initiates proof-of-concept study of ICA-105665 in photosensitive epilepsy

E.C. grants Gilead Sciences conditional marketing approval for Cayston

ASP-2151 inhibits VZV and HSV-1/-2 activity in vitro and reduces HSV-1 pathology in vivo

Shionogi and GSK report data from phase II trials of HIV integrase inhibitor S/GSK-1349572

ZT-031 shows favorable PK as intranasal formulation in preclinical evaluation

4SC-201 shows favorable oral profile and tolerability in patients with solid tumors

BIIB-022 shown to be safe in phase I trial in relapsed/refractory solid tumor patients

NicOx discovers NO donors for the treatment of hypertension and other conditions

HDAC inhibitors for the treatment of cancer presented by Roche

Boehringer Ingelheim claims BK1 receptor antagonists as analgesics

Cycloindole derivatives for the treatment of HCV infection described by iTherX

Cephalon discloses histamine H3 antagonists for the treatment of sleep disorders

NicOx submits NDA to FDA for naproxcinod in osteoarthritis

FDA grants accelerated approval to Allos Therapeutics' Folotyn for relapsed or refractory PTCL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...